To view the fulltext, please log in
To view the pdf, please log in
Dose selection for brain metastasis radiosurgery is based largely upon clinical data obtained over a half century of radiosurgical treatments for various benign and malignant conditions. It is expected that within the entire radiosurgical process, the step of dose selection will occur within a framework of accurate calibration of dose delivery and accurate and detailed imaging for planning the radiosurgical treatment. Brain metastasis radiosurgery should seek lifelong, uncomplicated control. A low radiosurgery dose that will not control the tumor will not achieve this therapeutic goal, and neither will a radiosurgery dose that controls the tumor but causes symptomatic brain radiation necrosis. The volume of the metastasis being targeted and the volume of normal tissues receiving substantial radiosurgical doses are of paramount importance in dose selection. A high degree of conformality of the high-dose radiosurgical treatment volume to the metastasis has been shown to decrease complications, as does a steep dose gradient between the metastasis and adjacent normal brain tissue. A dose-escalation trial conducted by the Radiation Therapy Oncology Group that differentially dose-escalated radiosurgical doses for tumors of different sizes established that single-fraction doses between 15 and 24 Gy are relatively safe in patients who have received prior fractionated radiation therapy to the brain. Corresponding data do not exist for patients who are treated with primary radiosurgery and no whole brain radiation therapy. A dose-escalation trial for three-fraction radiosurgical treatment of brain metastases is being conducted at Stanford. Knowledge of prior whole brain radiation therapy treatment details, including the dose delivered and the time interval since that treatment was given may affect the choice of radiosurgical dose, as may recent administration of systemic, radiation-potentiating chemotherapy. Physician knowledge and careful judgment, together with careful treatment planning and delivery can minimize the risks associated with brain metastasis radiosurgery.
Copyright / Drug Dosage
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
- Leksell L: Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry 1983;46:797-803
- Steiner L, Forster D, Leksell L, Meyerson BA, Boëthius J: Gammathalamotomy in intractable pain. Acta Neurochir (Wien) 1980;52:173-184
- Leksell L, Herner T, Leksell D, Persson B, Lindquist C: Visualisation of stereotactic radiolesions by nuclear magnetic resonance. J Neurol Neurosurg Psychiatry 1985;48:19-20
- Wilson RR: Radiological use of fast protons. Radiology 1946;47:487-91
- Lawrence JH: Proton irradiation of the pituitary. Cancer 1957;10:795-798
- Lawrence JH, Tobias CA, Born JL, McCombs RK, Roberts JE, Anger HO, Low-Beer BV, Huggins CB: Pituitary irradiation with high-energy proton beams: a preliminary report. Cancer Res 1958;18:121-134
- A Pinpoint Beam Strays Invisibly, Harming Instead of Healing. http://www.nytimes.com/2010/12/29/health/29radiation.html accessed 4/2/2011
- Tsai JS, Rivard MJ, Engler MJ, Mignano JE, Wazer DE, Shucart WA: Determination of the 4 mm Gamma Knife helmet relative output factor using a variety of detectors. Med Phys 2003;30:986-992
- Sze G, Johnson C, Kawamura Y, Goldberg SN, Lange R, Friedland RJ, Wolf RJ: Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 1998;19:821-828
- Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ: The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 1995;16:373-380
- Paddick I: A simple scoring ratio to index the conformity of radiosurgical treatment plans. Technical note. J Neurosurg 2000;93:(suppl 3)219-222
- Paddick I, Lippitz B: A simple dose gradient measurement tool to complement the conformity index. J Neurosurg 2006;105:(suppl)194-201
- Baumert BG, Rutten I, Dehing-Oberije C, Twijnstra A, Dirx MJ, Debougnoux-Huppertz RM, Lambin P, Kubat B: A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys 2006;66:187-194
- Neves S, Mazal PR, Wanschitz J, Rudnay AC, Drlicek M, Czech T, Wüstinger C, Budka H: Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin Neuropathol 2001;20:38-42
- Noël G, Simon JM, Valery CA, Cornu P, Boisserie G, Hasboun D, Ledu D, Tep B, Delattre JY, Marsault C, Baillet F, Mazeron JJ: Radiosurgery for brain metastasis: Impact of CTV on local control. Radiother Oncol 2003;68:15-21
- Nataf F, Schlienger M, Liu Z, Foulquier JN, Grès B, Orthuon A, Vannetzel JM, Escudier B, Meder JF, Roux FX, Touboul E: Radiosurgery with or without a 2-mm margin for 93 single brain metastases. Int J Radiat Oncol Biol Phys 2008;70:766-772
- Shaw E, Scott C, Souhami L, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 2000;47:291-298
- Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006;295:2483-2491
- http://clinicaltrials.gov/ct2/show/NCT00928226 accessed 4/2/2011